Skip to main content
SpringerLink
Log in

Adverse Effects of Acne Medications: Recognition and Management

  • Therapy in Practice
  • Published:
American Journal of Clinical Dermatology Aims and scope Submit manuscript

Abstract

Acne vulgaris is a very common chronic inflammatory disease of the skin. The clinical features of acne range from non-inflammatory comedones to inflammatory nodules. While often perceived as an adolescent disease, the prevalence remains high into adulthood, and the manifestations can have detrimental psychosocial effects. It is therefore not surprising that many patients are motivated to seek treatment. The existing treatment strategies for acne are complex due to the multifactorial pathogenesis of the disease. Although it is difficult to cure, four categories of medications have proved efficacious in reducing acne lesions: topical agents, systemic antibiotics, systemic retinoids, and hormonal agents. Unfortunately, these medications can cause adverse effects that may limit their use. Typically, these adverse effects are mild and transient and can be remedied by altering the dose or frequency of the offending agent. However, more serious adverse effects can occur that pose a significant health risk to the patient. Understanding how to recognize and manage the adverse effects of common acne therapies is imperative to providing the safest and most appropriate treatment for each patient. This article focuses on the recognition and management of adverse effects associated with current acne medications.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Dawson AL, Dellavalle RP. Acne vulgaris. BMJ. 2013;346(7907):30–3.

    Google Scholar 

  2. Shalita AR. Acne: clinical presentations. Clin Dermatol. 2004;22(5):385–6.

    PubMed  Google Scholar 

  3. Williams HC, Dellavalle RP, Garner S. Acne vulgaris. Lancet. 2012;379(9813):361–72.

    PubMed  Google Scholar 

  4. Degitz K, Placzek M, Borelli C, Plewig G. Pathophysiology of acne. JDDG J Dtsch Dermatol Ges. 2007;5(4):316–23.

    PubMed  Google Scholar 

  5. Webster GF. The pathophysiology of acne. Cutis. 2005;76(2 Suppl):4–7.

    PubMed  Google Scholar 

  6. Knutsen-Larson S, Dawson AL, Dunnick CA, Dellavalle RP. Acne vulgaris: pathogenesis, treatment, and needs assessment. Dermatol Clin. 2012;30(1):99–106.

    CAS  PubMed  Google Scholar 

  7. James WD. Acne. N Engl J Med. 2005;352(14):1463–72.

    CAS  PubMed  Google Scholar 

  8. Bowe WP, Glick JB, Shalita AR. Solodyn and updates on topical and oral therapies for acne. Curr Dermatol Rep. 2012;1(3):97–107.

    Google Scholar 

  9. Gollnick H, Schramm M. Topical drug treatment in acne. Dermatology. 1998;196(1):119–25.

    CAS  PubMed  Google Scholar 

  10. Aa Shalita, Weiss JS, Chalker DK, Ellis CN, Greenspan A, Katz HI, et al. A comparison of the efficacy and safety of adapalene gel 0.1 % and tretinoin gel 0.025 % in the treatment of acne vulgaris: a multicenter trial. J Am Acad Dermatol. 1996;34(3):482–5.

    Google Scholar 

  11. Bershad S, Singer GK, Parente JE, Tan M-H, Sherer DW, Persaud AN, et al. Successful treatment of acne vulgaris using a new method: results of a randomized vehicle-controlled trial of short-contact therapy with 0.1 % tazarotene gel. Arch Dermatol. 2002;138(4):481–9.

    CAS  PubMed  Google Scholar 

  12. Epstein EL, Gold LS. Safety and efficacy of tazarotene foam for the treatment of acne vulgaris. Clin Cosmet Investig Dermatol. 2013;6:123.

    CAS  PubMed Central  PubMed  Google Scholar 

  13. Shalita AR, Chalker DK, Griffith RF, Herbert AA, Hickman JG, Maloney JM, et al. Tazarotene gel is safe and effective in the treatment of acne vulgaris: a multicenter, double-blind, vehicle-controlled study. Cutis. 1999;63(6):349–54.

    CAS  PubMed  Google Scholar 

  14. Webster GF, Berson D, Stein LF, Fivenson DP, Tanghetti EA, Ling M. Efficacy and tolerability of once-daily tazarotene 0.1 % gel versus once-daily tretinoin 0.025 % gel in the treatment of facial acne vulgaris: a randomized trial. Cutis. 2001;67(6 Suppl):4–9.

    CAS  PubMed  Google Scholar 

  15. Cunliffe WJ, Poncet M, Loesche C, Verschoore M. A comparison of the efficacy and tolerability of adapalene 0.1 % gel versus tretinoin 0.025 % gel in patients with acne vulgaris: a meta-analysis of five randomized trials. Br J Dermatol. 1998;139(Suppl 52):48–56.

    CAS  PubMed  Google Scholar 

  16. Feldman S, Careccia RE, Barham KL, Hancox J. Diagnosis and treatment of acne. Am Fam Physician. 2004;69(9):2123–38.

    PubMed  Google Scholar 

  17. Akhavan A, Bershad S. Topical acne drugs. Am J Clin Dermatol. 2003;4(7):473–92.

    PubMed  Google Scholar 

  18. Loureiro KD, Kao KK, Jones KL, Alvarado S, Chavez C, Dick L, et al. Minor malformations characteristic of the retinoic acid embryopathy and other birth outcomes in children of women exposed to topical tretinoin during early pregnancy. Am J Med Genet Part A. 2005;136(2):117–21.

    PubMed  Google Scholar 

  19. Panchaud A, Csajka C, Merlob P, Schaefer C, Berlin M, Santis M, et al. Pregnancy outcome following exposure to topical retinoids: a multicenter prospective study. J Clin Pharmacol. 2012;52(12):1844–51.

    CAS  PubMed  Google Scholar 

  20. Becker LE, Bergstresser PR, Whiting DA, Clendenning WE, Dobson RL, Jordan WP, et al. Topical clindamycin therapy for acne vulgaris. A cooperative clinical study. Arch Dermatol. 1981;117(8):482–5.

    CAS  PubMed  Google Scholar 

  21. Draelos ZD, Carter E, Maloney JM, Elewski B, Poulin Y, Lynde C et al. Two randomized studies demonstrate the efficacy and safety of dapsone gel, 5 % for the treatment of acne vulgaris. J Am Acad Dermatol. 2007;56(3):439.e1–10.

  22. Goltz RW, Coryell GM, Schnieders JR, Neidert GL. A comparison of Cleocin T 1 percent solution and Cleocin T 1 percent lotion in the treatment of acne vulgaris. Cutis. 1985;36(3):265–8.

    CAS  PubMed  Google Scholar 

  23. Parker F. A comparison of clindamycin 1 % solution versus clindamycin 1 % gel in the treatment of acne vulgaris. Int J Dermatol. 1987;26(2):121–2.

    CAS  PubMed  Google Scholar 

  24. Simonart T, Dramaix M. Treatment of acne with topical antibiotics: lessons from clinical studies. Br J Dermatol. 2005;153(2):395–403.

    CAS  PubMed  Google Scholar 

  25. Milstone EB, McDonald AJ, Scholhamer CF. Pseudomembranous colitis after topical application of clindamycin. Arch Dermatol. 1981;117(3):154–5.

    CAS  PubMed  Google Scholar 

  26. Parry MF, Rha C-K. Pseudomembranous colitis caused by topical clindamycin phosphate. Arch Dermatol. 1986;122(5):583–4.

    CAS  PubMed  Google Scholar 

  27. Thomson Healthcare. Physicians’ desk reference: prescription drugs. 63rd ed. Montvale, NJ; 2009.

  28. Gollnick H, Cunliffe W, Berson D, Dreno B, Finlay A, Leyden JJ, et al. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol. 2003;49(1):S1–37.

    PubMed  Google Scholar 

  29. Leyden JJ. Bacterial resistance and therapeutic outcome following three months of topical acne therapy with 2 % erythromycin gel versus its vehicle. Acta Derm Venereol. 2002;82:260–5.

    PubMed  Google Scholar 

  30. Patel M, Bowe WP, Heughebaert C, Shalita AR. The development of antimicrobial resistance due to the antibiotic treatment of acne vulgaris: a review. J Drugs Dermatol. 2010;9(6):655–64.

    PubMed  Google Scholar 

  31. Thiboutot D, Gollnick H, Bettoli V, Dréno B, Kang S, Leyden JJ, et al. New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group. J Am Acad Dermatol. 2009;60(5):S1–50.

    PubMed  Google Scholar 

  32. Bowe WP, Shalita AR, editors. Effective over-the-counter acne treatments. Seminars in cutaneous medicine and surgery: Elsevier; 2008.

  33. Leyden JJ, Berger RS, Dunlap FE, Ellis CN, Connolly MA, Levy SF. Comparison of the efficacy and safety of a combination topical gel formulation of benzoyl peroxide and clindamycin with benzoyl peroxide, clindamycin and vehicle gel in the treatments of acne vulgaris. Am J Clin Dermatol. 2001;2(1):33–9.

    CAS  PubMed  Google Scholar 

  34. Mills OH, Kligman AM, Pochi P, Comite H. Comparing 2.5 %, 5 %, and 10 % benzoyl peroxide on inflammatory acne vulgaris. Int J Dermatol. 1986;25(10):664–7.

    PubMed  Google Scholar 

  35. Gehrig KA, Warshaw EM. Allergic contact dermatitis to topical antibiotics: epidemiology, responsible allergens, and management. J Am Acad Dermatol. 2008;58(1):1–21.

    PubMed  Google Scholar 

  36. Morelli R, Lanzarini M, Vincenzi C, Reggiani M. Contact dermatitis due to benzoyl peroxide. Contact Dermat. 1989;20(3):238–9.

    CAS  Google Scholar 

  37. Raschke R, Arnold-Capell PA, Richeson R, Curry SC. Refractory hypoglycemia secondary to topical salicylate intoxication. Arch Intern Med. 1991;151(3):591–3.

    CAS  PubMed  Google Scholar 

  38. Schwarb FP, Gabard B, Rufli T, Surber C. Percutaneous absorption of salicylic acid in man after topical administration of three different formulations. Dermatology (Basel, Switzerland). 1999;198(1):44–51 (18063 [pii]).

    CAS  PubMed  Google Scholar 

  39. Brubacher JR, Hoffman RS. Salicylism from topical salicylates: review of the literature. Clin Toxicol. 1996;34(4):431–6.

    CAS  Google Scholar 

  40. Pertoldi F, D’Orlando L, Mercante WP. Acute salicylate intoxication after trancutaneous absorption. Minerva Anestesiol. 1999;65(7–8):571–3.

    CAS  PubMed  Google Scholar 

  41. Kornhauser A, Coelho SG, Hearing VJ. Applications of hydroxy acids: classification, mechanisms, and photoactivity. Clin Cosmet Investig Dermatol. 2010;3:135–42. doi:10.2147/ccid.s9042.

    CAS  PubMed Central  PubMed  Google Scholar 

  42. Baumann LS, Oresajo C, Yatskayer M, Dahl A, Figueras K. Comparison of clindamycin 1 % and benzoyl peroxide 5 % gel to a novel composition containing salicylic acid, capryloyl salicylic acid, HEPES, glycolic acid, citric acid, and dioic acid in the treatment of acne vulgaris. J Drugs Dermatol. 2013;12(3):266–9.

    CAS  PubMed  Google Scholar 

  43. Picardo M, Ottaviani M. Azelaic acid. Pathogenesis and treatment of acne and rosacea. Berlin: Springer; 2014. p. 435–40.

    Google Scholar 

  44. Thiboutot D. New treatments and therapeutic strategies for acne. Arch Fam Med. 2000;9(2):179–87.

    CAS  PubMed  Google Scholar 

  45. Fitton A, Goa KL. Azelaic acid. Drugs. 1991;41(5):780–98.

    CAS  PubMed  Google Scholar 

  46. Kircik LH. Harnessing the anti-inflammatory effects of topical dapsone for management of acne. J Drugs Dermatol JDD. 2010;9(6):667–71.

    PubMed  Google Scholar 

  47. Piette WW, Taylor S, Pariser D, Jarratt M, Sheth P, Wilson D. Hematologic safety of dapsone gel, 5 %, for topical treatment of acne vulgaris. Arch Dermatol. 2008;144(12):1564–70.

    CAS  PubMed  Google Scholar 

  48. Fleischer AB Jr, Shalita A, Eichenfield LF, Abramovits W, Lucky A, Garrett S, et al. Dapsone gel 5 % in combination with adapalene gel 0.1 %, benzoyl peroxide gel 4 % or moisturizer for the treatment of acne vulgaris: a 12-week, randomized, double-blind study. J Drugs Dermatol JDD. 2010;9(1):33–40.

    PubMed  Google Scholar 

  49. Lucky AW, Maloney JM, Roberts J, Taylor S, Jones T, Ling M, et al. Dapsone gel 5 % for the treatment of acne vulgaris: safety and efficacy of long-term (1 year) treatment. J Drugs Dermatol JDD. 2007;6(10):981–7.

    PubMed  Google Scholar 

  50. Webster GF. Is topical dapsone safe in glucose-6-phosphate dehydrogenase-deficient and sulfonamide-allergic patients? J Drugs Dermatol JDD. 2010;9(5):532–6.

    PubMed  Google Scholar 

  51. Zakopoulou N, Kontochristopoulos G. Superficial chemical peels. J Cosmet Dermatol. 2006;5(3):246–53. doi:10.1111/j.1473-2165.2006.00254.x.

    CAS  PubMed  Google Scholar 

  52. Garg VK, Sinha S, Sarkar R. Glycolic acid peels versus salicylic-mandelic acid peels in active acne vulgaris and post-acne scarring and hyperpigmentation: a comparative study. Dermatol Surg Off Publ Am Soc Dermatol Surg [et al]. 2009;35(1):59–65. doi:10.1111/j.1524-4725.2008.34383.x.

    CAS  Google Scholar 

  53. Peric S, Bubanj M, Bubanj S, Jancic S. Side effects assessment in glicolyc acid peelings in patients with acne type I. Bosnian J Basic Med Sci Udruzenje basicnih mediciniskih znanosti Assoc Basic Med Sci. 2011;11(1):52–7.

    CAS  Google Scholar 

  54. Madan RK, Levitt J. A review of toxicity from topical salicylic acid preparations. J Am Acad Dermatol. 2014;70(4):788–92.

    CAS  PubMed  Google Scholar 

  55. Dreno B, Fischer TC, Perosino E, Poli F, Viera MS, Rendon MI, et al. Expert opinion: efficacy of superficial chemical peels in active acne management—what can we learn from the literature today? Evidence-based recommendations. J Eur Acad Dermatol Venereol JEADV. 2011;25(6):695–704. doi:10.1111/j.1468-3083.2010.03852.x.

    CAS  PubMed  Google Scholar 

  56. Meynadier J, Alirezai M. Systemic antibiotics for acne. Dermatology. 1998;196(1):135–9.

    CAS  PubMed  Google Scholar 

  57. Lebrun-Vignes B, Kreft-Jais C, Castot A, Chosidow O. Comparative analysis of adverse drug reactions to tetracyclines: results of a French national survey and review of the literature. Br J Dermatol. 2012;166(6):1333–41.

    CAS  PubMed  Google Scholar 

  58. Smith K, Leyden JJ. Safety of doxycycline and minocycline: a systematic review. Clin Ther. 2005;27(9):1329–42.

    CAS  PubMed  Google Scholar 

  59. Katsambas A, Papakonstantinou A. Acne: systemic treatment. Clin Dermatol. 2004;22(5):412–8.

    PubMed  Google Scholar 

  60. Khan Durani B, Jappe U. Drug-induced Sweet’s syndrome in acne caused by different tetracyclines: case report and review of the literature. Br J Dermatol. 2002;147(3):558–62.

    CAS  PubMed  Google Scholar 

  61. Lee AG. Pseudotumor cerebri after treatment with tetracycline and isotretinoin for acne. Cutis. 1995;55(3):165–8.

    CAS  PubMed  Google Scholar 

  62. Brown SK, Shalita AR. Acne vulgaris. Lancet. 1998;351(9119):1871–6.

    CAS  PubMed  Google Scholar 

  63. Shapiro LE, Knowles SR, Shear NH. Comparative safety of tetracycline, minocycline, and doxycycline. Arch Dermatol. 1997;133(10):1224–30.

    CAS  PubMed  Google Scholar 

  64. Tan H-H. Antibacterial therapy for acne. Am J Clin Dermatol. 2003;4(5):307–14.

    PubMed  Google Scholar 

  65. Alikhan A, Henderson GP, Becker L, Sciallis GF. Acne treatment and inflammatory bowel disease: what is the evidence? 1097–6787 (Electronic).

  66. Kronman MP, Zaoutis TE, Haynes K, Feng R, Coffin SE. Antibiotic exposure and IBD development among children: a population-based cohort study. Pediatrics. 2012;130(4):e794–803.

    PubMed Central  PubMed  Google Scholar 

  67. Margolis DJ, Fanelli M, Hoffstad O, Lewis JD. Potential association between the oral tetracycline class of antimicrobials used to treat acne and inflammatory bowel disease. Am J Gastroenterol. 2010;105(12):2610–6.

    CAS  PubMed  Google Scholar 

  68. Layton AM, Cunliffe WJ. Phototoxic eruptions due to doxycycline—a dose-related phenomenon. Clin Exp Dermatol. 1993;18(5):425–7.

    CAS  PubMed  Google Scholar 

  69. Garner SE, Eady EA, Popescu C, Newton J, Li WA. Minocycline for acne vulgaris: efficacy and safety. Cochrane Database Syst Rev. 2003;1:CD002086.

    PubMed  Google Scholar 

  70. Fanning WL, Gump DW, Sofferman RA. Side effects of minocycline: a double-blind study. Antimicrob Agents Chemother. 1977;11(4):712–7.

    CAS  PubMed Central  PubMed  Google Scholar 

  71. Goulden V, Glass D, Cunliffe WJ. Safety of long-term high-dose minocycline in the treatment of acne. Br J Dermatol. 1996;134(4):693–5.

    CAS  PubMed  Google Scholar 

  72. Williams D, Laughlin L, Lee Y-H. Minocycline: possible vestibular side-effects. Lancet. 1974;304(7883):744–6.

    Google Scholar 

  73. Donnet A, Dufour H, Graziani N, Grisoli F. Minocycline and benign intracranial hypertension. Biomed Pharmacother. 1992;46(4):171–2.

    CAS  PubMed  Google Scholar 

  74. Lessell S. Pediatric pseudotumor cerebri (idiopathic intracranial hypertension). Surv Ophthalmol. 1992;37(3):155–66.

    CAS  PubMed  Google Scholar 

  75. Monaco F, Agnetti V, Mutani R. Benign intracranial hypertension after minocycline therapy. Eur Neurol. 1978;17(1):48–9.

    CAS  PubMed  Google Scholar 

  76. Eisen D, Hakim MD. Minocycline-induced pigmentation. Drug Saf. 1998;18(6):431–40.

    CAS  PubMed  Google Scholar 

  77. Mouton RW, Jordaan HF, Schneider JW. A new type of minocycline-induced cutaneous hyperpigmentation. Clin Exp Dermatol. 2004;29(1):8–14.

    CAS  PubMed  Google Scholar 

  78. Collins P, Cotterill JA. Minocycline-induced pigmentation resolves after treatment with the Q-switched ruby laser. Br J Dermatol. 1996;135(2):317–9.

    CAS  PubMed  Google Scholar 

  79. Gough A, Chapman S, Wagstaff K, Emery P, Elias E. Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome. BMJ (Clinical research ed). 1996;312(7024):169–72.

    CAS  PubMed Central  Google Scholar 

  80. Knowles SR, Shapiro L, Shear NH. Serious adverse reactions induced by minocycline: report of 13 patients and review of the literature. Arch Dermatol. 1996;132(8):934–9.

    CAS  PubMed  Google Scholar 

  81. Wolkenstein P, Revuz J. Drug-induced severe skin reactions. Drug Saf. 1995;13(1):56–68.

    CAS  PubMed  Google Scholar 

  82. Yung RL, Richardson BC. Drug-induced lupus. Rheum Dis Clin North Am. 1994;20(1):61–86.

    CAS  PubMed  Google Scholar 

  83. Elkayam O, Yaron M, Caspi D, editors. Minocycline-induced autoimmune syndromes: an overview. Seminars in arthritis and rheumatism: Elsevier; 1999.

  84. Lawrenson RA, Seaman HE, Sundström A, Williams TJ, Farmer RDT. Liver damage associated with minocycline use in acne. Drug Saf. 2000;23(4):333–49.

    CAS  PubMed  Google Scholar 

  85. Bhambri S, Del Rosso JQ, Desai A. Oral trimethoprim/sulfamethoxazole in the treatment of acne vulgaris. Cutis. 2007;79(6):430–4.

    PubMed  Google Scholar 

  86. Lawson DH, Paice BJ. Adverse reactions to trimethoprim–sulfamethoxazole. Rev Infect Dis. 1982;4(2):429–33.

    CAS  PubMed  Google Scholar 

  87. Fernandez-Obregon AC. Azithromycin for the treatment of acne. Int J Dermatol. 2000;39(1):45–50.

    CAS  PubMed  Google Scholar 

  88. Kapadia N, Talib A. Acne treated successfully with azithromycin. Int J Dermatol. 2004;43(10):766–7.

    PubMed  Google Scholar 

  89. Ray WA, Murray KT, Hall K, Arbogast PG, Stein CM. Azithromycin and the risk of cardiovascular death. N Engl J Med. 2012;366(20):1881–90.

    CAS  PubMed Central  PubMed  Google Scholar 

  90. Thiboutot D. Acne: hormonal concepts and therapy. Clin Dermatol. 2004;22(5):419–28.

    PubMed  Google Scholar 

  91. George R, Clarke S, Thiboutot D, editors. Hormonal therapy for acne. Seminars in cutaneous medicine and surgery: WB Saunders; 2008.

  92. Harper JC. Antiandrogen therapy for skin and hair disease. Dermatol Clin. 2006;24(2):137–43.

    CAS  PubMed  Google Scholar 

  93. Harper JC. Should dermatologists prescribe hormonal contraceptives for acne? Dermatol Ther. 2009;22(5):452–7.

    PubMed  Google Scholar 

  94. Katsambas AD, Dessinioti C. Hormonal therapy for acne: why not as first line therapy? Facts and controversies. Clin Dermatol. 2010;28(1):17–23.

    PubMed  Google Scholar 

  95. Haider A, Shaw JC. Treatment of acne vulgaris. JAMA. 2004;292(6):726–35.

    CAS  PubMed  Google Scholar 

  96. Lidegaard Ø, Nielsen LH, Skovlund CW, Skjeldestad FE, Løkkegaard E. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001–2009. BMJ. 2011;343:d6423.

  97. Shaw JC, White LE. Long-term safety of spironolactone in acne: results of an 8-year followup study. JCMS. 2002;6(6):541–5.

    Google Scholar 

  98. Yemisci A, Gorgulu A, Piskin S. Effects and side-effects of spironolactone therapy in women with acne. J Eur Acad Dermatol Venereol. 2005;19(2):163–6.

    CAS  PubMed  Google Scholar 

  99. Shaw JC. Low-dose adjunctive spironolactone in the treatment of acne in women: a retrospective analysis of 85 consecutively treated patients. J Am Acad Dermatol. 2000;43(3):498–502.

    CAS  PubMed  Google Scholar 

  100. Van Wayjen RGA, Van den Ende A. Experience in the long-term treatment of patients with hirsutism and/or acne with cyproterone acetate-containing preparations: efficacy, metabolic and endocrine effects. Exp Clin Endocrinol Diabetes. 1995;103(04):241–51.

    PubMed  Google Scholar 

  101. Brahm J, Brahm M, Segovia R, Latorre R, Zapata R, Poniachik J, et al. Acute and fulminant hepatitis induced by flutamide: case series report and review of the literature. Ann Hepatol. 2011;10(1):93–8.

    PubMed  Google Scholar 

  102. Strauss JS, Krowchuk DP, Leyden JJ, Lucky AW, Shalita AR, Siegfried EC, et al. Guidelines of care for acne vulgaris management. J Am Acad Dermatol. 2007;56(4):651–63.

    PubMed  Google Scholar 

  103. Wysowski DK, Freiman JP, Tourtelot JB, Horton ML. Fatal and nonfatal hepatotoxicity associated with flutamide. Ann Intern Med. 1993;118(11):860–4.

    CAS  PubMed  Google Scholar 

  104. Ward A, Brogden RN, Heel RC, Speight TM, Avery GS. Isotretinoin. Drugs. 1984;28(1):6–37.

    CAS  PubMed  Google Scholar 

  105. McLane J. Analysis of common side effects of isotretinoin. J Am Acad Dermatol. 2001;45(5):S188–94.

    CAS  PubMed  Google Scholar 

  106. Strauss JS, Gottlieb AB, Jones T, Koo JY, Leyden JJ, Lucky A, et al. Concomitant administration of vitamin E does not change the side effects of isotretinoin as used in acne vulgaris: a randomized trial. J Am Acad Dermatol. 2000;43(5 Pt 1):777–84. doi:10.1067/mjd.2000.110391.

    CAS  PubMed  Google Scholar 

  107. Kus S, Gun D, Demircay Z, Sur H. Vitamin E does not reduce the side-effects of isotretinoin in the treatment of acne vulgaris. Int J Dermatol. 2005;44(3):248–51. doi:10.1111/j.1365-4632.2004.02072.x.

    CAS  PubMed  Google Scholar 

  108. Hull PR, Demkiw-Bartel C. Isotretinoin use in acne: prospective evaluation of adverse events. J Cutan Med Surg. 2000;4(3):66–70.

    CAS  PubMed  Google Scholar 

  109. Kmiec ML, Pajor A, Broniarczyk-Dyla G. Evaluation of biophysical skin parameters and assessment of hair growth in patients with acne treated with isotretinoin. Postepy Dermatol Alergol. 2013;30(6):343–9. doi:10.5114/pdia.2013.39432.

    PubMed Central  PubMed  Google Scholar 

  110. Tan B, Lear J, Smith A. Acne fulminans and erythema nodosum during isotretinoin therapy responding to dapsone. Clin Exp Dermatol. 1997;22(1):26–7.

    CAS  PubMed  Google Scholar 

  111. Seukeran D, Cunliffe W. The treatment of acne fulminans: a review of 25 cases. Br J Dermatol. 1999;141:307–9.

    CAS  PubMed  Google Scholar 

  112. Charakida A, Mouser P, Chu A. Safety and side effects of the acne drug, oral isotretinoin. Expert Opin Drug Saf. 2004;3(2):119–29.

    CAS  PubMed  Google Scholar 

  113. Bigby M, Stern RS. Adverse reactions to isotretinoin: a report from the Adverse Drug Reaction Reporting System. J Am Acad Dermatol. 1988;18(3):543–52.

    CAS  PubMed  Google Scholar 

  114. Roytman M, Frumkin A, Bohn TG. Pseudotumor cerebri caused by isotretinoin. Cutis. 1988;42(5):399–400.

    CAS  PubMed  Google Scholar 

  115. Shalita AR, Cunningham WJ, Leyden JJ, Pochi PE, Strauss JS. Isotretinoin treatment of acne and related disorders: an update. J Am Acad Dermatol. 1983;9(4):629–38.

    CAS  PubMed  Google Scholar 

  116. Crockett SD, Porter CQ, Martin CF, Sandler RS, Kappelman MD. Isotretinoin use and the risk of inflammatory bowel disease: a case–control study. Am J Gastroenterol. 2010;105(9):1986–93.

    PubMed Central  PubMed  Google Scholar 

  117. Reddy D, Siegel CA, Sands BE, Kane S. Possible association between isotretinoin and inflammatory bowel disease. Am J Gastroenterol. 2006;101(7):1569–73.

    CAS  PubMed  Google Scholar 

  118. Ellis CN, Krach KJ. Uses and complications of isotretinoin therapy. J Am Acad Dermatol. 2001;45(5):S150–7.

    CAS  PubMed  Google Scholar 

  119. Landau M, Mesterman R, Ophir J, Mevorah B, Alcalay J, Harel A, et al. Clinical significance of markedly elevated serum creatine kinase levels in patients with acne on isotretinoin. Acta Derm Venereol. 2001;81(5):350–2.

    CAS  PubMed  Google Scholar 

  120. Ladizinski B, Lee KC, Federman DG. Hypertriglyceridemia: what the dermatologist needs to know. JAMA Dermatol. 2013;149(10):1145–6. doi:10.1001/jamadermatol.2013.4316.

    PubMed  Google Scholar 

  121. Mantel-Teeuwisse AK, Kloosterman JM, Maitland-van der Zee AH, Klungel OH, Porsius AJ, de Boer A. Drug-induced lipid changes. Drug Saf. 2001;24(6):443–56.

    CAS  PubMed  Google Scholar 

  122. Altman RS, Altman LJ, Altman JS. A proposed set of new guidelines for routine blood tests during isotretinoin therapy for acne vulgaris. Dermatology. 2001;204(3):232–5.

    Google Scholar 

  123. Azoulay L, Blais L, Koren G, LeLorier J, Berard A. Does isotretinoin increase the risk of depression? J Clin Psychiatry. 2008;69(4):526–32.

    CAS  PubMed  Google Scholar 

  124. Dunn LK, O’Neill JL, Feldman SR. Acne in adolescents: quality of life, self-esteem, mood and psychological disorders. Dermatol Online J. 2011;17(1).

  125. Jacobs DG, Deutsch NL, Brewer M. Suicide, depression, and isotretinoin: is there a causal link? J Am Acad Dermatol. 2001;45(5):S168–75.

    CAS  PubMed  Google Scholar 

  126. Kontaxakis VP, Skourides D, Ferentinos P, Havaki-Kontaxaki BJ, Papadimitriou GN. Isotretinoin and psychopathology: a review. Ann Gen Psychiatry. 2009;8(2).

  127. Magin P, Pond D, Smith W. Isotretinoin, depression and suicide: a review of the evidence. Br J Gener Pract J Royal Coll Gener Pract. 2005;55(511):134–8.

    Google Scholar 

  128. Bérard A, Azoulay L, Koren G, Blais L, Perreault S, Oraichi D. Isotretinoin, pregnancies, abortions and birth defects: a population-based perspective. Br J Clin Pharmacol. 2007;63(2):196–205.

    PubMed Central  PubMed  Google Scholar 

  129. Lammer EJ, Chen DT, Hoar RM, Agnish ND, Benke PJ, Braun JT, et al. Retinoic acid embryopathy. N Engl J Med. 1985;313(14):837–41.

    CAS  PubMed  Google Scholar 

  130. Werner CA, Papic MJ, Ferris LK, Schwarz EB. Promoting safe use of isotretinoin by increasing contraceptive knowledge. JAMA Dermatol. doi:10.1001/jamadermatol.2014.4171. Epub 4 Feb 2015.

Download references

Acknowledgments

No sources of funding were used to prepare this review. None of the authors have conflicts of interest that are directly related to the content of this review.

Author information

Authors and Affiliations

  1. Department of Dermatology, University of North Carolina School of Medicine, 410 Market Street, #400, Chapel Hill, NC, 27516, USA

    Mollie D. Oudenhoven, Megan A. Kinney, Diana B. McShane, Craig N. Burkhart & Dean S. Morrell

Authors
  1. Mollie D. Oudenhoven
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Megan A. Kinney
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Diana B. McShane
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Craig N. Burkhart
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Dean S. Morrell
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dean S. Morrell.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Oudenhoven, M.D., Kinney, M.A., McShane, D.B. et al. Adverse Effects of Acne Medications: Recognition and Management. Am J Clin Dermatol 16, 231–242 (2015). https://doi.org/10.1007/s40257-015-0127-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40257-015-0127-7

Keywords

Search

Navigation